Submitted Phase II study protocol to the U.S. Food and Drug Administration (FDA) for a randomized, head-to-head Phase II study comparing EscharEx to collagenase in VLU patients. This trial ...
17d
Initiated VALUE, a global Phase III pivotal trial of EscharEx® for venous leg ulcersExpanded strategic research collaborations with industry ...
What you need to know about the advantages and risks of investing in private equity. We sell different types of products and services to both investment professionals and individual investors ...
MediWound Ltd (NASDAQ: MDWD) reported its fourth-quarter 2024 earnings, showcasing a better-than-expected performance with an EPS of -0.36, surpassing the forecasted -0.56. Revenue for the quarter ...
"2024 was a pivotal year for MediWound, marked by strong execution, clinical progress, and strategic collaborations,” said Ofer Gonen, CEO of MediWound. "The initiation of the VALUE Phase III pivotal ...
Optimization of Collagenase Proteomics for Improved Mass Spectrometry Imaging Peptide Identification
Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina 29425, United States ...
A public consultation on proposed changes to this document was held from December 2024 to March 2025. Based on the feedback received, this document may change. Learn about the consultation. Drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback